Marketing-authorisation holder · Canada
Sanofi-Aventis Canada Inc
235 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
235 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 235
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ADMELOG100 unit / ml · Solution | Insulin lispro | Canada | Marketed | 2019 |
| ADMELOG100 unit / ml · Solution | Insulin lispro | Canada | Marketed | 2019 |
| ADMELOG SOLOSTAR100 unit / ml · Solution | Insulin lispro | Canada | Marketed | 2019 |
| ALDURAZYME0.58 mg / ml · Solution | Laronidase | Canada | Marketed | 2004 |
| ALPROLIX250 unit / vial · Kit, Powder For Solution | Coagulation factor ix | Canada | Authorised | |
| ALPROLIX3000 unit / vial · Kit, Powder For Solution | Coagulation factor ix | Canada | Marketed | 2016 |
| ALPROLIX2000 unit / vial · Kit, Powder For Solution | Coagulation factor ix | Canada | Marketed | 2015 |
| ALPROLIX500 unit / vial · Kit, Powder For Solution | Coagulation factor ix | Canada | Marketed | 2015 |
| ALPROLIX1000 unit / vial · Kit, Powder For Solution | Coagulation factor ix | Canada | Marketed | 2016 |
| ALPROLIX4000 unit / vial · Kit, Powder For Solution | Coagulation factor ix | Canada | Authorised | |
| ALTUVIIIO1000 unit / vial · Powder For Solution | Antihemophilic factor | Canada | Marketed | 2025 |
| ALTUVIIIO2000 unit / vial · Powder For Solution | Antihemophilic factor | Canada | Marketed | 2025 |
| ALTUVIIIO3000 unit / vial · Powder For Solution | Antihemophilic factor | Canada | Marketed | 2025 |
| ALTUVIIIO500 unit / vial · Powder For Solution | Antihemophilic factor | Canada | Marketed | 2025 |
| ALTUVIIIO4000 unit / vial · Powder For Solution | Antihemophilic factor | Canada | Marketed | 2025 |
| ALTUVIIIO250 unit / vial · Powder For Solution | Antihemophilic factor | Canada | Authorised | |
| APIDRA100 unit / ml · Solution | Insulin glulisine | Canada | Marketed | 2009 |
| APIDRA100 unit / ml · Solution | Insulin glulisine | Canada | Marketed | 2008 |
| APIDRA100 unit / ml · Solution | Insulin glulisine | Canada | Marketed | 2008 |
| ARAVA10 mg · Tablet | Leflunomide | Canada | Marketed | 2000 |
| ARAVA20 mg · Tablet | Leflunomide | Canada | Marketed | 2000 |
| AVALIDE12.5 mg + 150 mg · Tablet | Hydrochlorothiazide, Irbesartan | Canada | Marketed | 2000 |
| AVALIDE12.5 mg + 300 mg · Tablet | Hydrochlorothiazide, Irbesartan | Canada | Marketed | 2000 |
| AVAPRO300 mg · Tablet | Irbesartan | Canada | Marketed | 1998 |
| AVAPRO150 mg · Tablet | Irbesartan | Canada | Marketed | 1998 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 235 | 99 | 136 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.